Novel wearable technologies measured cardiac function and machine-learning algorithms to assess patients with compensated and decompensated HF, according to a study published in Circulation: Heart Failure.
“An important characteristic of the patch system described here is that, in addition to hemodynamic measurements, high-quality ECG-based heart rate and rhythm and accelerometer-based activity data are also inherently collected,” Omer T. Inan, PhD, assistant professor at the School of Electrical and Computer Engineering at Georgia Institute of Technology in Atlanta, and colleagues wrote. “Thus, the seismocardiogram-derived features are supplementing existing technologies rather than attempting to replace them, providing the opportunity for fused metrics of improving or worsening condition using a single wearable device.”
Researchers analyzed data from 45 patients with compensated (n = 32; mean age, 57 years; 69% men) or decompensated HF (n = 13; mean age, 50 years; 85% men). The decompensated HF group was assessed upon hospital admission and discharge, and the compensated HF group was assessed during an outpatient clinic visit.
Patients wore a custom wireless patch that was mounted midsternum that measured ECG and seismocardiogram signals. All patients were required to rest for 60 seconds, perform a 6-minute walk test then rest for 5 minutes for the wearable patch to take the proper measurements. A simple graph-matching approach was then used to quantify structural changes in the seismocardiogram signal before and after a patient performed a 6-minute walk test.
Patients with decompensated HF had a higher calculated graph similarity score value (44.4) compared with those with compensated HF (35.2; P < .001).
Six-minute walk test distance was higher in the compensated HF group (369 m) vs. the decompensated HF group (250 m; P < .01).
The graph similarity score between the rest and recovery phases of the test was 44 at admission and 35 at discharge in six decompensated patients who had longitudinal data (P < .05).
“These techniques can be tested in the future to track the clinical status of outpatients with HF and their response to pharmacological interventions,” Inan and colleagues wrote. – by Darlene Dobkowski
Inan reports he has consulting/advisory board relationships with Physiowave.